Deals > All

Ireland United Kingdom East/South/London Midlands North & Yorkshire Northern Ireland Scotland Wales

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2611 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Deal: Collaboration or Financing	Date
Owlstone–Aviva: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Aviva Ventures	2025-01-15
Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation	2025-01-15
Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures	2025-01-15
Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital	2025-01-15
Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital	2025-01-15
Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation	2025-01-14
IDRx–GSK: investment, 202501– acquisition 100% of IDRx for $1b upfront + $150m milestones by GSK	2025-01-13
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities	2025-01-10
Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One	2025-01-10
Coave Therapeutics–Seroba: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Seroba Life Sciences	2025-01-09
Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio	2025-01-09
Ottimo Pharma–Avoro Capital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Avoro Capital	2024-12-19
Ottimo Pharma–Decheng Capital: investment, 202412 financing round Series A totalling >$140m incl co-investor Decheng Capital	2024-12-19
Ottimo Pharma–Invus Group: investment, 202412 financing round Series A totalling >$140m incl co-investor Invus	2024-12-19
Ottimo Pharma–Janus Henderson: investment, 202412 financing round Series A totalling >$140m incl co-investor Janus Henderson Investors	2024-12-19
Ottimo Pharma–JPMorgan Chase: investment, 202412 financing round Series A totalling >$140m incl co-investor JP Morgan Life Sciences Private Capital	2024-12-19
Ottimo Pharma–Medicxi Ventures: investment, 202412 financing round Series A totalling >$140m incl existing + co-investor Medicxi	2024-12-19
Ottimo Pharma–OrbiMed: investment, 202412 financing round Series A totalling >$140m incl co-lead investor OrbiMed	2024-12-19
Ottimo Pharma–RTW Investments: investment, 202412 financing round Series A totalling >$140m incl co-investor RTW Investments	2024-12-19
Ottimo Pharma–Samsara BioCapital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Samsara BioCapital	2024-12-19
Ottimo Pharma–SEVERAL: investment, 202412 financing round Series A >$140m led by OrbiMed + Avoro Capital + Samsara BioCapital	2024-12-19
VectorY–Vigo Consulting: public relations, 202412 service existent by Vigo Consulting	2024-12-16
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments	2024-12-12
BenevolentAI–ICR: public relations, 202412 service existent by ICR Healthcare Europe	2024-12-11
Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi	2024-12-10
GSK–Relation Therapeutics: drug target discovery, 202412– two collab $30m upfront + $263m milestones + royalties in fibrotic diseases + osteoarthritis	2024-12-10
Relation Therapeutics–GSK: investment, 202412 equity investment $15m in connection with strategic collaborations	2024-12-10
Citryll–ICR: public relations, 202412 service existent by ICR Healthcare Europe	2024-12-09
GSK–Muna Therapeutics: drug target discovery, 202412– collab strategic alliance €33.5m upfront + milestones MiND-MAP platform for Alzheimer targets	2024-12-05
Newcells Biotech–SEVERAL: investment, 202412 financing round £1.2m from existing investors Mercia Ventures + Northstar Ventures + North East Finance	2024-12-05
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures	2024-12-04
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures	2024-12-04
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures	2024-11-26
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP	2024-11-26
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital	2024-11-26
Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP	2024-11-26
Doccla–Bertelsmann: investment, <=202411 investment by existing investor Bertelsmann Investments	2024-11-07
Kynos Therapeutics–Falk Pharma: investment, 202410 acquisition of Kyno Therapeutics Ltd by Dr Falk Pharma GmbH	2024-10-29
Ottimo Pharma–Optimum Strategic Communications: public relations, 202410 service existent by Optimum	2024-10-28
Seaport Therapeutics–PureTech Health: investment, 202410 financing round Series B totalling $225m incl existing + co-investor PureTech Health	2024-10-21
Nuclera–Cambridge Innovation Capital: investment, 202410 financing round Series C totalling $75m incl co-investor Cambridge Innovation Capital	2024-10-16
Nuclera–E Ink: investment, 202410 financing round Series C totalling $75m incl existing + co-investor E Ink Holdings	2024-10-16
Nuclera–GK Goh: investment, 202410 financing round Series C totalling $75m incl existing + co-investor GK Goh	2024-10-16
Nuclera–M&G: investment, 202410 financing round Series C totalling $75m incl existing + co-investor M&G Catalyst	2024-10-16
Nuclera–Patient Square Capital: investment, 202410 financing round Series C totalling $75m incl lead investor Elevage Medical Technologies	2024-10-16
Nuclera–PERSON: investment, 202410 financing round Series C totalling $75m incl co-investor Jonathan Milner	2024-10-16
Nuclera–PERSON: investment, 202410 financing round Series C totalling $75m incl co-investor Michael D McCreary	2024-10-16
Nuclera–SEVERAL: investment, 202410 financing round Series C $75m led by Elevage Medical Technologies (Patient Square Capital)	2024-10-16
Nuclera–Uni Power Group: investment, 202410 financing round Series C totalling $75m incl co-investor Uni Power Group	2024-10-16
Nuclera–United Kingdom (govt): investment, 202410 financing round Series C totalling $75m incl co-investor British Patient Capital	2024-10-16
Nuclera–Verve Capital Partners: investment, 202410 financing round Series C totalling $75m incl co-investor Verve Ventures	2024-10-16
Antiverse–SEVERAL: investment, 202410 seed financing round 2nd extension £3.5m led by i&i Bio + Kadmos Capital	2024-10-15
Shift Bioscience–BGF: investment, 202410 seed financing round totalling £12.5m incl lead investor BGF	2024-10-15
Shift Bioscience–F-Prime: investment, 202410 seed financing round totalling £12.5m incl existing + co-investor F-Prime Capital	2024-10-15
Shift Bioscience–Kindred Capital: investment, 202410 seed financing round totalling £12.5m incl existing + co-investor Kindred Capital	2024-10-15
Shift Bioscience–PERSON: investment, 202410 seed financing round totalling £12.5m incl existing + co-investor Jonathan Milner	2024-10-15
Shift Bioscience–SEVERAL: investment, 202410 seed financing round £12.5m led by BGF	2024-10-15
Shift Bioscience–Zyme Communications: public relations, 202410 service existent by Zyme	2024-10-15
Clock Bio–BY Capital: investment, 202410 seed financing round totalling $5.3m incl co-investor BlueYard Capital	2024-10-09
Clock Bio–Onsight Ventures: investment, 202410 seed financing round totalling $5.3m incl co-investor Onsight Ventures	2024-10-09
Clock Bio–PERSON: investment, 202410 seed financing round totalling $5.3m incl co-investor Jonathan Milner	2024-10-09
Clock Bio–Phoenix Court Group: investment, 202410 seed financing round totalling $5.3m incl lead investor LocalGlobe	2024-10-09
Clock Bio–SEVERAL: investment, 202410 seed financing round $5.3m led by LocalGlobe	2024-10-09
Purespring Therapeutics–ICR: public relations, 202410 service existent ICR Consilium is media contact	2024-10-09
Purespring Therapeutics–SEVERAL: investment, 202410 financing round Series B £80m led by Sofinnova Partners	2024-10-09
Somagenetix–Schroders: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor Schroders Capital	2024-10-08
Somagenetix–SEVERAL: investment, 202410 financing round Series A CHF10m first closing led by Vi Partners	2024-10-08
Enara Bio–Francis Crick Institute: investment, 202410 financing round Series B totalling $32.5m incl new + co-investor Francis Crick Institute	2024-10-03
Enara Bio–Merck (DE): investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor M Ventures	2024-10-03
Enara Bio–Pfizer: investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor Pfizer Ventures	2024-10-03
Enara Bio–RA Capital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor RA Capital	2024-10-03
Enara Bio–Samsara BioCapital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor Samsara BioCapital	2024-10-03
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures	2024-10-03
Enara Bio–SV Health Investors: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor SV Health Investors	2024-10-03
LoQus23 Therapeutics–Forbion: investment, 202410 financing round Series A totalling £35m incl new + lead investor Forbion	2024-10-02
LoQus23 Therapeutics–Novartis: investment, 202410 financing round Series A totalling £35m incl existing + co-investor Novartis Venture Fund	2024-10-02
LoQus23 Therapeutics–Optimum Strategic Communications: public relations, 202410 service existent by Optimum	2024-10-02
LoQus23 Therapeutics–SEVERAL: investment, 202410 financing round Series A £35m led by new investor Forbion	2024-10-02
LoQus23 Therapeutics–SV Health Investors: investment, 202410 financing round Series A totalling £35m incl existing + co-investor DDF	2024-10-02
Constructive Biology–SEVERAL: investment, 202409 financing round Series A first closing $58m led by Ahren + OMX Ventures + Paladin Capital	2024-09-24
Lift BioSciences–SEVERAL: investment, 202409 financing round Series A first closing £10m	2024-09-24
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama	2024-09-18
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries	2024-09-16
Solasta Bio–SEVERAL: investment, 202409 financing round Series A $14m led by Forbion BioEconomy Fund	2024-09-11
Formo Bio–SEVERAL: investment, 202409 financing round Series B $61m from existing + new investors	2024-09-10
NanoSyrinx–BGF: investment, 202409 financing round totalling £10m incl co-lead investor BGF	2024-09-10
NanoSyrinx–IQ Capital: investment, 202409 financing round totalling £10m incl existing + co-investor IQ Capital	2024-09-10
NanoSyrinx–Lilly: investment, 202409 financing round totalling £10m incl new + co-investor Eli Lilly	2024-09-10
NanoSyrinx–Meltwind: investment, 202409 financing round totalling £10m incl existing + co-investor Meltwind	2024-09-10
NanoSyrinx–Merck (DE): investment, 202409 financing round totalling £10m incl existing + co-lead investor M Ventures	2024-09-10
NanoSyrinx–Octopus Investments: investment, 202409 financing round totalling £10m incl existing + co-lead investor Octopus Ventures	2024-09-10
NanoSyrinx–SEVERAL: investment, 202409 financing round £10m co-led by BGF + Octopus Ventures + M Ventures	2024-09-10
NanoSyrinx–Zyme Communications: public relations, 202409 service existent by Zyme	2024-09-10
PhoreMost–SEVERAL: investment, 202409 financing round Series B extension $12m bringing total round to $50m led by Parkwalk Advisors	2024-09-10
Sofinnova–Optimum Strategic Communications: public relations, 202409 service existent by Optimum for Sofinnova Partners	2024-09-10
Immunocore–Danaher: data management software, 202409– supply Genedata SDMS for discovery of TCR therapeutics	2024-09-05
BioStrata–Supreme Optimization: investment, 202408 acquisition of BioStrata by Supreme Group	2024-08-21
Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility	2024-08-15
Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m	2024-08-15
Balderton Capital–SEVERAL: investment, 202408 announced $615m Early Stage Fund IX	2024-08-12

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)